Social News
Written by: Chen Qianting
2020-05-09 06:37
Last update date: 2020-05-09 06:37A new study by Yuan Guoyong, a lecturer professor of the Department of Microbiology at the University of Hong Kong, and his team shows that the current "cocktail therapy" for patients with new coronavirus pneumonia is to mix three antiviral drugs, interferon, protease inhibitors and ribavirin Use, within an average of 7 days after the start of treatment, the patient's nasopharyngeal swab sample has no virus detected, and the effect of inhibiting the virus is faster than the average of 12 days for patients with protease inhibitors alone.
Yuan Guoyong pointed out that cocktail therapy can shorten the period of virus transmission and relieve patients' symptoms faster, and the hospital stay was also reduced by 5.5 days. The research object is patients with mild to moderate symptoms. The team said that this is only a second-phase clinical trial. It is still necessary to understand the effect of cocktail therapy on severe patients in the third-phase trial. The latest research results are in the famous medical journal "Needling Needle" "(Lancet) published.
The latest research from the Department of Microbiology of the University of Hong Kong Medical College has proved that cocktail therapy can shorten the treatment period of new pneumonia, and patients leave the hospital on average 5.5 days earlier. (Profile picture)
Cocktail therapy covers three antiviral drugs, including a combination of protease inhibitors and ribavirin, which effectively reduced respiratory failure and mortality during SARS in 2003, and animal studies of interferon in the Middle East Respiratory Syndrome can help reduce the virus Load capacity and improve lung disease.
Study subjects are patients with mild to moderate symptoms
The research team recruited 127 confirmed patients with new pneumonia from six public hospitals in Hong Kong. The average age is 52 years old. The patient's condition is mild to moderate. All nasopharyngeal swab samples were positive for the new virus.
The team randomly divided the patients into two groups and received a two-week drug treatment. There were 86 patients in the cocktail therapy group, 34 of whom were more than 7 days old. They would take protease inhibitors and ribavirin. Others in the same group Fifty-two patients had symptoms on or less than 7 days. In addition to the above two drugs, interferon was also injected. As for the control group, a total of 41 patients will only be assigned protease inhibitors.
The Chinese Center for Disease Control and Prevention released the gene sequence and images of the new coronavirus early this year. (Source: IVDC, China CDC)
Therapy speeds up the suppression of the amount of virus, and the drug has no virus for 7 days
The results of the study showed that the patients who used cocktail therapy had no virus detected in the nasopharyngeal swab samples within an average of 7 days after the start of treatment, and the effect was more significant than the average of 12 days for the patients in the control group. In addition, the clinical symptoms of cocktail therapy patients took an average of 4 days to improve, and the control group patients took 8 days, the treatment time was reduced by half. In terms of the number of hospitalization days, patients on cocktail therapy were discharged on average within 9 days, and were discharged 5.5 days earlier than the control group's 14.5 days.
The patients in this study had no obvious side effects, but only one patient in the control group developed severe liver dysfunction during the study period, and treatment was discontinued. The most common symptoms of other patients are diarrhea, fever and nausea.
Yuan Guoyong described the clinical trial results as encouraging and showed that cocktail therapy was quite safe. (Information picture / photo by Luo Junhao)
Yuan Guoyong: Reduce the transmission period of the virus and reduce the infection risk of medical staff
Yuan Guoyong, the chair professor of the Department of Microbiology at the University of Hong Kong, who led the research, described the encouraging clinical trial results, showing that cocktail therapy seems to be quite safe and can quickly suppress the amount of virus in the patient ’s body. During the transmission period, reduce the risk of infections faced by medical staff.
In the past, the medical community was concerned that if a patient had been sick for more than a week, taking interferon might cause an immune storm, which could be fatal. The 52 patients with interferon injected in this study had better clinical status and pathological data than patients in the control group who received treatment at the same time. The team believes that it may mean that interferon is the key to cocktail therapy and is worth further research.
Yuan Guoyong also emphasized that the next step is to do a larger phase III clinical trial to find out whether the treatment of interferon alone or in combination with other drugs is effective for patients with more serious conditions.
HKU study reveals that the new coronavirus is more susceptible to infection of the conjunctiva than the SARS
HKU research indicates that population movements in Wuhan affect the national epidemic and more Shenzhen patients than expected
New Coronary Pneumonia│Hong Kong Government allocates 111 million to Hong Kong University, Zhongda University to develop vaccines and serum epidemiological studies
【New Coronary Pneumonia】 Hong Kong University Research Journal "Needle" estimates that more than 230,000 people have been infected in the Mainland in mid-February
Yuan Guanyong, New Coronary Pneumonia Medical College
